{
    "clinical_study": {
        "@rank": "102519", 
        "arm_group": [
            {
                "arm_group_label": "Adolescents (13-17yrs)", 
                "arm_group_type": "Experimental", 
                "description": "Adolescent subjects with ADHD"
            }, 
            {
                "arm_group_label": "Children (6-11 yrs)", 
                "arm_group_type": "Experimental", 
                "description": "Pediatric subjects with ADHD"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will be conducted in 2 separate stages, the first in adolescents and the second\n      in children. Both Stages 1 and 2 will use an adaptive, single or multiple cohort open-label,\n      single-treatment, fasting design examining the pharmacokinetic (PK) effects of up to 2\n      separate modified release formulations (B and C) of HLD200 (54 mg)."
        }, 
        "brief_title": "Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining Pk of Two MR Formulations of MPH in Adolescent/Pediatric Subjects With ADHD", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Attention-Deficit Hyperactivity Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female adolescents (13-17 years; Stage 1) and children (6-12 years; Stage\n             2).\n\n          -  Previous diagnosis of ADHD and confirmation using the Mini International\n             Neuropsychiatric Interview for Children and Adolescents (MINI-KID).\n\n          -  ADHD symptoms controlled on a stable dose of ADHD medication. Subjects should be on\n             MPH or have previous history of symptom control during treatment with MPH.\n\n          -  Physical examination free of clinically significant findings, unless deemed NCS by\n             the Investigator and Medical Monitor;\n\n          -  Able to swallow treatment capsules;\n\n          -  Available for entire study period;\n\n          -  Provision of informed consent (from the parent[s] and/or legal representative[s]) and\n             assent (from the subject); and\n\n          -  Female subjects of childbearing potential (i.e., post-menarche) required to have a\n             negative result on urine pregnancy testing (and will be given specific instructions\n             on avoiding pregnancy during trial)\n\n        Exclusion Criteria:\n\n          -  Any known history or presence of significant cardiovascular, pulmonary, hepatic,\n             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,\n             neurologic, ophthalmologic disease, unless deemed NCS by the Investigator and the\n             Medical Monitor;\n\n          -  Presence of any significant physical or organ abnormality;\n\n          -  Any illness during the 4 weeks before this study, unless deemed NCS by the\n             Investigator and the Clinical and/or Medical Monitor;\n\n          -  Severe comorbid psychiatric diagnosis that may affect subject safety or confound\n             results (e.g., psychosis, bipolar disorder);\n\n          -  Known history of moderate to severe asthma;\n\n          -  Known history of severe allergic reaction (including drugs, food, insect bites,\n             environmental allergens);\n\n          -  Known history of seizures (except febrile seizures prior to age 5), anorexia nervosa,\n             bulimia or current diagnosis or family history of Tourette's disorder;\n\n          -  Subject who are severely underweight or overweight.\n\n          -  Clinical value outside of the acceptable ranges, unless deemed NCS significant per\n             the Investigator;\n\n          -  Positive history for hepatitis B, hepatitis C and Human Immunodeficiency Virus (HIV);\n\n          -  Positive screening for illicit drug use, and/or current health conditions or use of\n             medications that might confound the results of the study or increase risk to the\n             subject;\n\n          -  Use of prescription medications (except ADHD medications) within 7 days and over-the\n             counter medications (except birth control) within the 3 days preceding study\n             enrollment, unless deemed acceptable by the Investigator and Clinical and/or Medical\n             Monitor;\n\n          -  Blood draws of 50 ml to 249 ml within the 30 days, 250 ml to 449 ml within the 45\n             days and \u2265 450 ml within the 60 days preceding study enrollment;\n\n          -  Participation in clinical trial with an investigational drug within the 30 days\n             preceding study enrollment;\n\n          -  Intolerance to venipuncture; and\n\n          -  Current suicidal ideation or history of suicidality determined as a significant\n             finding on the Columbia-Suicide Severity Rating Scale (C-SSRS) by the investigator\n             (Baseline C-SSRS for adolescents; Pediatric Baseline C-SSRS for children)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907360", 
            "org_study_id": "HLD200-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Adolescents (13-17yrs)", 
                    "Children (6-11 yrs)"
                ], 
                "intervention_name": "HLD200 (B formulation)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Adolescents (13-17yrs)", 
                    "Children (6-11 yrs)"
                ], 
                "intervention_name": "HLD200 (C formulation)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 9, 2013", 
        "location": {
            "contact": {
                "last_name": "Ann Childress, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Las Vegas", 
                    "country": "United States", 
                    "state": "Nevada", 
                    "zip": "89128"
                }, 
                "name": "Centre for Psychiatry & Behavioral Medicine, Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining the Pharmacokinetic Effects of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.", 
        "overall_contact": {
            "email": "bert@ironshorepharma.com", 
            "last_name": "Bert DeSousa, MA", 
            "phone": "905-869-6964"
        }, 
        "overall_official": {
            "affiliation": "Centre for Psychiatry & Behavioral Medicine, Inc.", 
            "last_name": "Ann Childress, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the rate and extent of absorption of MPH utilizing the following parameters: AUC0-tz, AUC0-\u221e, Cmax, Tmax, absorption lag time, \u03bbz, and t1/2elim.", 
            "measure": "PK", 
            "safety_issue": "No", 
            "time_frame": "48hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907360"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A secondary endpoint will include safety and tolerability and will be assessed by clinical monitoring of blood pressure, pulse rate, laboratory data, suicidality and the reporting of adverse events.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "48hrs"
        }, 
        "source": "Ironshore Pharmaceuticals and Development, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ironshore Pharmaceuticals and Development, Inc", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}